USDA licenses long-acting injectable for canine allergic dermatitisNovember 12, 2026 With a 75-day dosing interval, the monoclonal antibody (mAb) treatment helps reduce the number of clinic visits required for managing allergic dermatitis and lower the risk of missed doses.
Education Center - SponsoredHow AI-Enabled Diagnostic Platforms are Buying Back Time for Veterinarians and Cliniciansby • Zoetis DiagnosticsIn the right context, AI yields the power to enhance clinical confidence and streamline decision-making – without replacing the human touch that defines the profession.
A close look at monoclonal antibodies for managing canine OA painJanuary 15, 2026As veterinary care continues to shift toward preventive medicine and lifelong wellness, there is growing momentum around improving earlier detection and more consistent pain management. Among the emerging therapeutic options is a new class of biologics: monoclonal antibodies (mAbs).
Monoclonal antibody (mAb) product innovation aim of facility expansion in KansasAugust 23, 2024A $130-million investment through 2026 is expected to bolster production and development of monoclonal antibody-based therapy, including a potential product in canine dermatology.